{"disease":{"id":"wet-age-related-macular-degeneration-amd","name":"wet age related macular degeneration amd"},"drugs":{"marketed":[{"drug_id":"ranibizumab-eqrn","indication_name":"Neovascular (Wet) Age-Related Macular Degeneration (AMD)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"CIMERLI","generic_name":"RANIBIZUMAB-EQRN","company_name":"SANDOZ INC","drug_phase":"marketed","molecular_target":"","drug_class":"Vascular Endothelial Growth Factor Inhibitor [EPC]","quality_score":18,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04270747","title":"A Study to Understand Effectiveness and Safety of ABP 938 Compared to Aflibercept (Eylea®) in Patients Suffering With Neovascular Age-related Macular Degeneration [Neovascular (Wet) AMD]","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":576,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT01972789","title":"Comparison of Treatment Regimens Using Ranibizumab: Intensive (Resolution of Intra- and Sub-retinal Fluid) vs Relaxed (Resolution of Intra-retinal Fluid and/or Sub-retinal Fluid >200µm at the Foveal Centre)","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":349,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT07185841","title":"Safety and Efficacy of Oral HX9428 Tablets in Subjects With Wet Age-related Macular Degeneration (wAMD)","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":198,"lead_sponsor_name":"Fujian Haixi Pharmaceuticals Co., Ltd.","has_results":false},{"nct_id":"NCT06839339","title":"Efficacy and Safety of AL-001 Ophthalmic Injection in Subjects with WAMD","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":40,"lead_sponsor_name":"Beijing Anlong Biopharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT06718816","title":"Long-term Follow-up Study of AL-001 Ophthalmic Injection in Subjects with WAMD","phase":"","overall_status":"RECRUITING","enrollment_count":21,"lead_sponsor_name":"Beijing Anlong Biopharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT06707753","title":"Safety and Tolerability of AL-001 Ophthalmic Injection in Subjects with WAMD","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":21,"lead_sponsor_name":"Beijing Anlong Biopharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT05903794","title":"A Study of EXG102-031 in Patients With wAMD (Everest)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":12,"lead_sponsor_name":"Exegenesis Bio","has_results":false},{"nct_id":"NCT06888492","title":"To Evaluate the Safety and Preliminary Efficacy of Intravitreal EXG202 Injection in Patients with Wet (neovascular) Age-related Macular Degeneration (wAMD)","phase":"EARLY_PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":8,"lead_sponsor_name":"Guangzhou Jiayin Biotech Ltd","has_results":false},{"nct_id":"NCT06398080","title":"An Observational Study to Investigate the Use of Aflibercept 8 mg to Treat Adult Patients With Neovascular Age-Related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME) in a Real-World Setting","phase":"","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":false}],"total":9},"guidelines":[],"source":"Drug Landscape verified database"}